Trials / Unknown
UnknownNCT02416999
Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hebei Yanda Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.
Detailed description
This trial is aimed at evaluating the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas. And, this trial is approved by medical ethics committee of Hebei Yanda Hospital.Researchers will conduct thsi trial from 2015/05 to 2018/05, and 30 recurrent high-grade glioma patients will be recruited. Patients who are recruited will get treatment of ultra-low dose Bevacizumab plus Temozolomide in ether Hebei Yanda Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ultra-low dose Bevacizumab | |
| DRUG | Temozolomide |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2018-05-01
- Completion
- 2018-05-01
- First posted
- 2015-04-15
- Last updated
- 2016-02-18
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02416999. Inclusion in this directory is not an endorsement.